LIVZON PHARMA (01513) Products Included in National Reimbursement Drug List

Stock News
Dec 08, 2025

LIVZON PHARMA (01513) announced that on December 7, 2025, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued the "National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance (2025)" (Document No. 33 [2025]). The details of the group's products included in the NRDL are as follows:

In 2025, a total of 194 products from the group were included in the NRDL, comprising 92 Class A and 102 Class B drugs. Notably, Aripiprazole Extended-Release Injectable Suspension was newly added to the NRDL through price negotiations, Triptorelin Acetate Extended-Release Injectable Suspension gained expanded indications, and Sodium Ilaprazole for Injection was successfully renewed.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10